Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanezumab in Osteoarthritis of the Knee
NCT01089725Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Mar 2010
- Primary completion
- Nov 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tanezumab in osteoarthritis (OA) (5 arms), sponsored by Pfizer. Primary endpoints: Western Ontario and McMaster Universities Osteoarthritis Index Pain Subscale at 16 weeks, Western Ontario and McMaster Universities Osteoarthritis Index Physical Function Subscale at 16 weeks and 1 more. Started Mar 2010; status: terminated.
02
Drugs
tanezumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT01089725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01089725.